度洛西汀治疗中枢介导的腹痛综合征的疗效研究  

Efficacy of Duloxetine in Treatment of Central Mediated Abdominal Pain Syndrome

作　　者：王玥[1] 许婷 乔月芹 崔艳欣[1] WANG Yue;XU Ting;QIAO Yueqin;CUI Yanxin(Department of Gastroenterology, Qingdao Municipal Hospital Affiliated to Qingdao University, Qingdao, Shandong Province ,266000)

机构地区：[1]青岛大学附属青岛市市立医院消化内科,266000

出　　处：《胃肠病学》2020年第11期666-669,共4页Chinese Journal of Gastroenterology

摘　　要：背景:中枢介导的腹痛综合征(CAPS)相关的功能性胃肠病是一种常见疾病。抗抑郁类药物在临床上可用于治疗CAPS,但CAPS的治疗仍缺乏典型的代表药物和足够的临床数据。目的:评估度洛西汀对CAPS的疗效。方法:纳入2017年1月—2019年12月青岛市市立医院收治的143例CAPS患者,并随机分为度洛西汀组和安慰剂组,采用简明疼痛评估量表(BPI)评估治疗效果。结果:与安慰剂相比,度洛西汀对CAPS的平均疼痛评分、过去24 h内最痛评分、最轻度疼痛评分、目前疼痛评分均明显改善,对日常生活、情绪、生活兴趣、行走能力、睡眠、与他人关系、日常工作的影响亦显著改善。6.8%的度洛西汀患者出现治疗引起的不良事件,包括恶心、口干、便秘和头痛。结论:度洛西汀对改善CAPS有显著作用,且安全性良好。Background:Central mediated abdominal pain syndrome(CAPS)related functional gastrointestinal disorders(FGIDs)is a commonly seen disease.Although the efficacy of antidepressants in treatment of CAPS has been reported,yet there is still lack of typical representative drugs and sufficient clinical data.Aims:To evaluate the efficacy of duloxetine in CAPS.Methods:A total of 143 patients with CAPS from Jan.2017 to Dec.2019 at Qingdao Municipal Hospital were enrolled and randomly divided into duloxetine group and placebo group.Brief pain inventory(BPI)was used to evaluate the efficacy.Results:Compared with placebo group,duloxetine significantly improved the average pain,the most painful in the past 24 hours,as well as the minimum pain and present pain in the patients with CAPS,and the impact on daily life,emotion,interest in life,walking ability,sleep,interpersonal relationship,working was significantly improved in duloxetine group.6.8%of patients in duloxetine group had treatment-induced adverse events,including nausea,dry mouth,constipation,and headache.Conclusions:Duloxetine can improve CAPS,and the safety in use is well.

关 键 词：度洛西汀 中枢介导的腹痛综合征 治疗 安全 

分 类 号：R47[医药卫生—护理学]